跳至主要内容
临床试验/NCT01211730
NCT01211730已完成4 期

Prospective, Randomized, Open-Label, Controlled Study to Evaluate the Safety and Efficacy of Intensive Glycemic Control on Outcomes Following Liver Transplantation

Northwestern University1 个研究点 分布在 1 个国家目标入组 164 人开始时间: 2009年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
164
试验地点
1
主要终点
Rejection of Liver Transplant

研究概览

简要总结

Many but not all studies have shown improvement in morbidity and mortality with intensive glycemic management postoperatively. In this study, the investigators propose to determine whether improved glycemic control using intensive insulin treatment immediately postoperatively will improve outcomes in patients undergoing liver transplant using a prospective, controlled, randomized, parallel-group study design targeting two different glucose levels, 140 and 180 mg/dL.

详细描述

Many studies have shown improvement in morbidity and mortality with intensive glycemic management postoperatively. However, some recent studies have not been able to reproduce these benefits and have raised the issue of adverse consequences of hypoglycemia associated with intensive therapy. Our own data show an association of increased graft rejection proportional to postoperative glucose levels in patients who have undergone a liver transplant. Preliminary data suggest that this may improved by better glycemic control using the Glucose Management Service here at Northwestern.

In this study, we propose to determine whether improved glycemic control using intensive insulin treatment immediately postoperatively will improve outcomes in patients undergoing liver transplant using a prospective, controlled, randomized, parallel-group study design targeting two different glucose levels, 140 and 180 mg/dL. Postoperative glucose management with insulin will be supervised by the Glucose Management Service as is routine, with the only research aspect being the two different glucose targets and the outcome analysis with liver transplant rejection as the primary outcome and infections and hypoglycemia being the principle secondary outcomes.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Require Liver Transplantation
  • Age 18 - 80
  • Able to give informed consent personally or via a family member who has appropriate authorization to do so if patient unconscious.
  • Expected survival following transplantation for > 1 year.
  • Glucose level over 180 mg/dL postoperatively

排除标准

  • Inability of patient or family member to give informed consent
  • Not expected to survive for > 1 year following liver transplantation.
  • Previous liver transplantation
  • Acute liver failure
  • Living related donor

研究组 & 干预措施

140 Group

Active Comparator

Insulin treatment to target blood glucose at 140 mg/dl

干预措施: Insulin (Drug)

180 Group

Active Comparator

Insulin treatment to target blood glucose at 180 mg/dl

干预措施: Insulin (Drug)

结局指标

主要结局

Rejection of Liver Transplant

时间窗: within 1 year of transplantation

Liver transplant rejection determined by either biopsy or clinical criteria (\>2x transaminases, clinical decision, treatment with high dose steroids and other anti-rejection medications

次要结局

  • Infection Rates(Within 1 year following transplantation)
  • Rehospitalization Rates(Within 1 year following transplantation)
  • Overall Graft Survival at 1 Year(1 year following transplantation)
  • Death Within 1 Year(1 year)
  • Hypoglycemia(Within first 3 days following transplantation)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Mark Molitch

Professor of Medicine

Northwestern University

研究点 (1)

Loading locations...

相似试验

已完成
3 期
Study Comparing Efficacy and Safety of Mycophenolate Mofetil (Cellcept) With Delayed Introduction of Sirolimus and Discontinuation of Cyclosporine, With Those of Mycophenolate Mofetil and Long Term Continuation of Cyclosporine in Renal Transplant RecipientsRenal Transplantation
NCT02686619Hoffmann-La Roche237
尚未招募
3 期
A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)Advanced Breast Cancer
NCT05753865CSPC Ouyi Pharmaceutical Co., Ltd.454
招募中
不适用
Clinical, prospective, randomised and controlled multicentric split-mouth study to evaluate the healing of an extraction socket with and without autologous, xenogenic or alloplastic bone substitute materialalveolar ridge atrophieK08.2Atrophy of edentulous alveolar ridge
DRKS00026275Klinik- fur Mund-, Kiefer- und Gesichtschirurgie30
进行中(未招募)
1 期
Prospective, randomized and controlled clinical trial comparing i.v. bolus application of Abciximab to i.c.application of Abciximab during primary PCU in patients with acute ST-elevation myocardial infarction - Abciximab-STEMIST-elevation myocardial infarctionMedDRA version: 9.1Level: LLTClassification code 10000891Term: Acute myocardial infarction
EUCTR2007-007864-63-DEniversity of Leipzig2,065
已完成
不适用
Prospective, controlled trial on safety and efficacy of compression stockings for patients with CVI and pAVK (Angioflow2)I73.9I87.2I70.2Peripheral vascular disease, unspecifiedVenous insufficiency (chronic)(peripheral)Atherosclerosis of arteries of extremities
DRKS00013978St. Josef und St. Elisabeth Hospital gGmbHKlinik für Dermatologie, Venerologie und Allergologie55